Sarcopenia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1 Meets sarcopenia diagnostic criteria: Patients at high risk for sarcopenia are screened according to the 2025 Asian Working Group for Sarcopenia (AWGS) consensus, specifically achieving a total score of >= 4 on the SARC-F questionnaire (Strength, Assistance with Walking, Rise from a Chair, Climb Stairs and Falls, SARC-F) >= 4 points, or calf circumference (CC) = 11 points; 2 Age >= 50 years; 3 Meeting the following levels based on the diagnostic criteria in the Chinese Expert Consensus on Prevention and Intervention of Sarcopenia in Older Adults (2023) for physical function assessment or grip strength testing: Physical function assessment: Using the 6-meter walk test method, diagnostic cutoff <1.0 m/s; Grip strength: <28 kg for males, <18 kg for females; 4 Body composition assessment: Bioelectrical impedance analysis (BIA) <7.0 kg/m^² for males, <5.7 kg/m^² for females; 5 Able to perform activities of daily living independently without requiring special care, free from harmful habits such as alcohol abuse or smoking; 6 Has not been away from primary residence for extended periods within the past six months and is not expected to leave residence within the next six months. 7 Sign an informed consent form. (Among criteria 2, 3, and 4 above, criterion 2must be met, along with either criterion 3 or 4.)
Exclusion criteria
Exclusion criteria: 1 Individuals with organ dysfunction include: heart failure, myocardial infarction within the past 6 months, unstable angina or stroke, severe chronic obstructive pulmonary disease, active gastrointestinal bleeding, inflammatory bowel disease, severe malabsorption disorders, dysphagia, uncontrolled diabetes, hyperthyroidism, Cushing's syndrome, malignancy, immune system disorders, moderate to severe cognitive impairment, Parkinson's disease, neurological disorders with severe motor dysfunction, limb dysfunction, or sensory impairments; 2 Individuals with severe psychiatric disorders unable to cooperate with study requirements; 3 Patients with a history of major surgery (e.g., hip replacement, pacemaker implantation, cardiac stenting, tumor resection, intestinal surgery); 4 Patients with secondary muscle wasting due to disease or medication, or those on long-term drugs affecting muscle or protein absorption/utilization (e.g., chemotherapy agents, diuretics); 5 Individuals who have undergone resistance training within the past 6 months; 6 Those requiring specialized medical formula support; 7 Individuals unable to tolerate standard dietary intervention; 8 Strictly vegan individuals.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| grip strength;Body composition;Complete Blood Count;Blood Biochemistry;Liver and kidney function;Urinalysis;Fecal Routine;Gut microbiota; | — |
Secondary
| Measure | Time frame |
|---|---|
| pace;Glycated hemoglobin;Insulin;Fasting blood glucose; | — |
Countries
China
Contacts
Southeast University; Zhongda Hospital Southeast University